Compare CNVS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | ACET |
|---|---|---|
| Founded | 2000 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 71.3M |
| IPO Year | 2016 | 2017 |
| Metric | CNVS | ACET |
|---|---|---|
| Price | $3.10 | $7.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $65.33 |
| AVG Volume (30 Days) | ★ 434.7K | 183.6K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $0.45 |
| 52 Week High | $7.39 | $9.05 |
| Indicator | CNVS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 70.72 | 53.90 |
| Support Level | $2.47 | $0.62 |
| Resistance Level | $3.49 | $8.74 |
| Average True Range (ATR) | 0.29 | 0.63 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 79.65 | 46.63 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.